›› 2008, Vol. 7 ›› Issue (7): 354-356.

• 论著 • Previous Articles     Next Articles

Daytime continuous veno-venous hemodiafiltration in the treatment of renal failure following cardiac surgery

YU Lei, PAN Xiao-xue, GU Tian-xiang, SHI En-yi, FAN Qiu-ling, WANG Bo   

  1. Department of Cardiac Surgery, The First Hospital of China Medical University, Shenyang 110001, China.
  • Received:2008-03-05 Revised:1900-01-01 Online:2008-07-12 Published:2008-07-12

Abstract: 【Abstract】Objective To summarize the experiences about daytime continuous veno-venous hemodiafiltration (CVVHDF) as a post-operational treatment for renal dysfunction following cardiac surgery. Methods During the period from Feb. 2002 to Mar. 2008, a total of 12 patients with renal dysfunction following cardiac surgery underwent daytime CVVHDF. We observed their changes in heart rate (HR), central vein pressure (CVP), mean artery blood pressure (MAP), PaO2, renal function, pressor medication used, perioperative manifestations and prognosis after the treatment. Results In the 12 patients, 8 cases underwent on-pump coronary artery bypass grafting (CABG), 2 cases received off-pump CABG, and 2 cases underwent on-pump valve replacement. Daytime CVVHDF was performed for the 12 patients, and the dialysis lasted for 8~12 hours. After the first dialysis for 6 hours, HR, CVP, creatinine, BUN and dopamine used decreased significantly (P<0.05, as compared with those before dialysis), and MAP and PaO2 increased (P<0.05, as compared with those before dialysis). Two cases died in the perioperative period, 7 patients discharged from the hospital with renal function and urine volume recovering to the preopeartive levels and without the dialysis anymore, and the other 3 patients still needed regular dialysis treatment. The mean follow-up period was 36.90+29.06 months, and their life quality improved remarkably. Conclusion Daytime CVVHDF is an effective measure in the treatment of renal dysfunction following cardiac surgery.

Key words: Coronary artery bypass grafting, Renal dysfunction

CLC Number: